Ultomiris Drug Market Size, Share & Trends Report

Ultomiris Drug Market (2025 - 2030) Size, Share & Trends Analysis Report By Indication (PNH, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder), By End Use, By Distribution Channel, By Region, And Segment Forecasts

Market Segmentation

Ultomiris (Ravulizumab) Drug Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Generalized Myasthenia Gravis (gMG)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ultomiris (Ravulizumab) Drug End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Adult
- Pediatric
Ultomiris (Ravulizumab) Drug Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Ultomiris (Ravulizumab) Drug Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Ultomiris (Ravulizumab) Drug Market, by Indication
    - Paroxysmal Nocturnal Hemoglobinuria (PNH)
    - Atypical Hemolytic Uremic Syndrome (aHUS)
    - Generalized Myasthenia Gravis (gMG)
    - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - North America Ultomiris (Ravulizumab) Drug Market, by End Use
    - Adult
    - Pediatric
  - North America Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - U.S.
    - U.S. Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - U.S. Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - U.S. Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Canada
    - Canada Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Canada Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Canada Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Mexico
    - Mexico Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Mexico Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Mexico Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Europe
  - Europe Ultomiris (Ravulizumab) Drug Market, by Indication
    - Paroxysmal Nocturnal Hemoglobinuria (PNH)
    - Atypical Hemolytic Uremic Syndrome (aHUS)
    - Generalized Myasthenia Gravis (gMG)
    - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - Europe Ultomiris (Ravulizumab) Drug Market, by End Use
    - Adult
    - Pediatric
  - Europe Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - UK
    - UK Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - UK Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - UK Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Germany
    - Germany Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Germany Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Germany Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - France
    - France Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - France Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - France Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Italy
    - Italy Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Italy Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Italy Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Spain
    - Spain Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Spain Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Spain Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Denmark
    - Denmark Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Denmark Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Denmark Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Sweden
    - Sweden Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Sweden Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Sweden Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Norway
    - Norway Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Norway Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Norway Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Asia Pacific
  - Asia Pacific Ultomiris (Ravulizumab) Drug Market, by Indication
    - Paroxysmal Nocturnal Hemoglobinuria (PNH)
    - Atypical Hemolytic Uremic Syndrome (aHUS)
    - Generalized Myasthenia Gravis (gMG)
    - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - Asia Pacific Ultomiris (Ravulizumab) Drug Market, by End Use
    - Adult
    - Pediatric
  - Asia Pacific Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - China
    - China Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - China Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - China Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Japan
    - Japan Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Japan Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Japan Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - India
    - India Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - India Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - India Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Australia
    - Australia Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Australia Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Australia Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - South Korea
    - South Korea Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - South Korea Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - South Korea Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Thailand
    - Thailand Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Thailand Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Thailand Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Latin America
  - Latin America Ultomiris (Ravulizumab) Drug Market, by Indication
    - Paroxysmal Nocturnal Hemoglobinuria (PNH)
    - Atypical Hemolytic Uremic Syndrome (aHUS)
    - Generalized Myasthenia Gravis (gMG)
    - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - Latin America Ultomiris (Ravulizumab) Drug Market, by End Use
    - Adult
    - Pediatric
  - Latin America Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - Brazil
    - Brazil Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Brazil Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Brazil Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Argentina
    - Argentina Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Argentina Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Argentina Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Middle East & Africa
  - Middle East & Africa Ultomiris (Ravulizumab) Drug Market, by Indication
    - Paroxysmal Nocturnal Hemoglobinuria (PNH)
    - Atypical Hemolytic Uremic Syndrome (aHUS)
    - Generalized Myasthenia Gravis (gMG)
    - Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - Middle East & Africa Ultomiris (Ravulizumab) Drug Market, by End Use
    - Adult
    - Pediatric
  - Middle East & Africa Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - South Africa
    - South Africa Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - South Africa Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - South Africa Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Saudi Arabia
    - Saudi Arabia Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Saudi Arabia Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Saudi Arabia Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - UAE
    - UAE Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - UAE Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - UAE Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Kuwait
    - Kuwait Ultomiris (Ravulizumab) Drug Market, by Indication
      - Paroxysmal Nocturnal Hemoglobinuria (PNH)
      - Atypical Hemolytic Uremic Syndrome (aHUS)
      - Generalized Myasthenia Gravis (gMG)
      - Neuromyelitis Optica Spectrum Disorder (NMOSD)
    - Kuwait Ultomiris (Ravulizumab) Drug Market, by End Use
      - Adult
      - Pediatric
    - Kuwait Ultomiris (Ravulizumab) Drug Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments